跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/ISRCTN45319897
ISRCTN45319897进行中（未招募）1 期

A Phase Ib, open-label, dose-escalation and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of inavolisib in combination with paclitaxel in patients with locally advanced or metastatic solid tumors

Genentech, Inc0 个研究点目标入组 104 人开始时间: 2021年7月7日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
1 期
状态
进行中（未招募）
入组人数
104
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • •Current inclusion criteria as of 20/07/2022:
  • •1. Signed Informed Consent Form
  • •2. Aged over 18 years and over
  • •3. Evaluable or measurable disease per RECIST, v1.1
  • •4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • •5. Life expectancy of >12 weeks
  • •6. Adequate hematologic and organ function within 14 days prior to initiation of study treatment, defined by the following:
  • •6.1. Absolute neutrophil count 1500/µl
  • •6.2. Hemoglobin =9 g/dl
  • •6.3. Platelet count =100,000/l
  • •6.4. Fasting glucose <126 mg/dL or <7 mmol/l and glycosylated hemoglobin (HbA1C) 5.7% or <39 millimoles per mole (mmol/mol)
  • •6.5. Total bilirubin <1.5 upper limit of normal (ULN)
  • •6.6. Serum albumin =2.5 g/dl or 25 g/l
  • •6.7. AST and ALT =2.5 ULN with the following exception: patients with documented liver metastases may have AST and ALT =5.0 ULN.
  • •6.8. Serum creatinine 1.5 ULN or creatinine clearance =50 ml/min on the basis of the Cockcroft-Gault glomerular filtration rate estimation
  • •6.9. International normalized ratio (INR) <1.5 x upper limit of normal (ULN) and activated partial thromboplastin time (aPTT) <1.5 x ULN
  • •7. Consent to provide fresh (preferred) or archival tumor tissue specimen. It is preferred that the specimen be from the most recently collected and available tumor tissue, and whenever possible, from a metastatic site of disease.
  • •8. Consent to provide a freshly collected pre-treatment blood sample.
  • •9. For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a highly effective form of contraceptive method with a failure rate of 1% per year in combination with use of male condom with spermicide (for male partners), unless male sterilization has been confirmed.
  • •10. For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use highly effective contraceptive measures, and agreement to refrain from donating sperm.
  • •Inclusion Criteria Specific to Patients Enrolling in Part 1, Arm A:
  • •Histologically documented, locally advanced, recurrent, or metastatic, incurable solid tumor malignancy that has progressed after available standard systemic therapies; or for whom standard therapy has proven to be ineffective or intolerable; or for whom a clinical trial of an investigational agent is a recognized standard of care. If there are other available SOC therapies, these will be discussed with the patient and documented before informed consent is obtained.
  • •Inclusion Criteria Specific to Patients Enrolling in Part 2, Arm A Expansion Cohorts:
  • •1. Histologically documented, locally advanced, recurrent, or metastatic, incurable solid tumor malignancy with a known PIK3CA mutation that has progressed after at least one available standard systemic therapy in the metastatic setting.
  • •– Cohort 1 (HNSCC): Histologically or cytologically confirmed recurrent and/or metastatic HNSCC that has been previously treated with systemic therapy in the recurrent and/or metastatic setting, which may include immunotherapy and/or chemotherapy with or without cetuximab.
  • •– Cohort 2 (ovarian cancer): Persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal tumors that have been previously treated with up to 4 prior regimens in the recurrent and/or metastatic setting, being at least one platinum-based. Patients may have received bevacizumab and/or poly-ADP ribose polymerase (PARP) inhibitors.
  • •– Cohort 3 (TNBC): Histologically or cytologically confirmed adenocarcinoma of the breast that is locall

排除标准

  • •1. Metaplastic breast cancer
  • •2. Any history of leptomeningeal disease
  • •3. Type 2 diabetes requiring ongoing systemic treatment at the time of study entry; or any history of Type 1 diabetes
  • •4. Inability or unwillingness to swallow pills
  • •5. Malabsorption syndrome or other condition that would interfere with enteral absorption
  • •6. Known and untreated, or active CNS metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control).
  • •7. Uncontrolled pleural effusion or ascites requiring recurrent drainage procedures twice per month or more frequently
  • •8. Any active infection that, in the opinion of the investigator, could impact patient safety; or, serious infection requiring IV antibiotics within 7 days prior to Day 1 of Cycle 1
  • •9. Any concurrent ocular or intraocular condition (e.g., cataract or diabetic retinopathy) that, in the opinion of the investigator or study ophthalmologist, would require medical or surgical intervention during the study period to prevent or treat vision loss that might result from that condition
  • •10. Active inflammatory (e.g., uveitis or vitritis) or infectious (e.g., conjunctivitis, keratitis, scleritis, or endophthalmitis) conditions in either eye or history of idiopathic or autoimmuneassociated uveitis in either eye
  • •11. Patients requiring any daily supplemental oxygen
  • •12. History of or active inflammatory disease (e.g., Crohn’s disease or ulcerative colitis), or any active bowel inflammation (including diverticulitis). Patients currently receiving immunosuppressants (e.g., sulfasalazines) are considered to have active disease; therefore, they are ineligible.
  • •13. Symptomatic hypercalcemia requiring continued use of bisphosphonate or denosumab therapy
  • •14. Clinically significant history of liver disease, including severe liver impairment (Child-Pugh Class B/C), viral or other hepatitis, current alcohol abuse, or cirrhosis
  • •15. Known HIV infection
  • •16. Any other diseases, active or uncontrolled pulmonary dysfunction, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, that may affect the interpretation of the results, or renders the patients at high risk from treatment complications
  • •17. Significant traumatic injury or major surgical procedure within 4 weeks prior to initiation of study treatment
  • •18. Radiation therapy (other than palliative radiation to bony metastases) as cancer therapy within 4 weeks prior to initiation of study treatment
  • •19. Palliative radiation to bony metastases within 2 weeks prior to initiation of study treatment
  • •20. Unresolved toxicity from prior therapy, except for the following: Alopecia Grade 1 and peripheral neuropathy
  • •21. Inability to comply with study and follow-up procedures
  • •22. History of other malignancy within 5 years prior to screening, with the exception of patients with a negligible risk of metastasis or death and/or treated with expected curative outcome (such as appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer)
  • •23. History of or active ventricular dysrhythmias or congestive heart failure requiring medication or coronary heart disease that is symptomatic
  • •24. Clinically significant electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia, hypocalcemia)

研究者

相似试验

尚未招募
1 期
Phase 1 Study of D3S-001 as Monotherapy in Subjects with Advanced Solid Tumors with a KRAS p.G12C Mutatio
JPRN-jRCT2031220703Kanemitsu Jun10
招募中
不适用
A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects with Advanced Solid TumorsAdvanced solid tumors: subjects withclear-cell renal cell carcinoma (referred to as RCC expansion cohort) and subjects with first-lineStage IIIB or IV nonsquamous non-small cell lung cancer (NSCLCreferred to as NSCLC expansion cohort). = renal cell carcinoma and nonsquamous non-small cell lung cancer10027656
NL-OMON54211MedImmune, LLC, a wholly owned subsidiary of AstraZeneca PLC10
进行中（未招募）
1 期
A study to test if different doses of D3S-001 used on its own are safe and tolerable in people with advanced solid tumors with KRAS p.G12C modificatio
CTIS2023-508517-16-00D3 Bio (Wuxi) Co. Ltd.165
招募中
1 期
A study to investigate the short- and long-term safety and tolerability of the drug SNDX-5613 in Patients with Relapsed/Refractory Leukemias. Various doses of SNDX-5613 will be investigated.
EUCTR2020-004104-34-ITSYNDAX PHARMACEUTICALS, INC.333
进行中（未招募）
1 期
A study to investigate the short- and long-term safety and tolerability of the drug SNDX-5613 in Patients with Relapsed/Refractory Leukemias. Various doses of SNDX-5613 will be investigated.
CTIS2024-513759-34-00Syndax Pharmaceuticals Inc.180